Search results for "NIST"

showing 10 items of 13738 documents

Mas receptor is involved in the estrogen-receptor induced nitric oxide-dependent vasorelaxation.

2017

The Mas receptor is involved in the angiotensin (Ang)-(1-7) vasodilatory actions by increasing nitric oxide production (NO). We have previously demonstrated an increased production of Ang-(1-7) in human umbilical vein endothelial cells (HUVEC) exposed to estradiol (E2), suggesting a potential cross-talk between E2 and the Ang-(1-7)/Mas receptor axis. Here, we explored whether the vasoactive response and NO-related signalling exerted by E2 are influenced by Mas. HUVEC were exposed to 10nM E2 for 24h in the presence or absence of the selective Mas receptor antagonist A779, and the estrogen receptor (ER) antagonist ICI182780 (ICI). E2 increased Akt and endothelial nitric oxide synthase (eNOS) …

0301 basic medicineMalemedicine.medical_specialtyEstrogen receptorVasodilationNitric OxideBiochemistryProto-Oncogene MasUmbilical veinNitric oxideReceptors G-Protein-Coupled03 medical and health scienceschemistry.chemical_compoundMiceEnosInternal medicineProto-Oncogene ProteinsmedicineHuman Umbilical Vein Endothelial CellsAnimalsHumansProtein kinase BPharmacologybiologyAntagonistbiology.organism_classificationMice Inbred C57BLVasodilation030104 developmental biologyEndocrinologychemistryReceptors EstrogenMyographBiochemical pharmacology
researchProduct

The metabolism of mono-(2-ethylhexyl) phthalate (MEHP) and liver peroxisome proliferation in the hamster.

1988

This study has investigated the in vivo metabolism of mono-(2-ethylhexyl) phthalate (MEHP), the initial metabolite of di-(2-ethylhexyl) phthalate in mammals, and the hepatic peroxisome proliferation induced by this compound following multiple oral administration to hamsters. Hamsters received [14C]-MEHP, by gavage, at doses of 50 and 500 mg/kg body wt on each of three consecutive days. Urine was collected every 24 hours and metabolite profiles were determined using capillary gas-chromatography. Multiple high doses of MEHP (500 mg/kg) induced a change in the relative proportions of metabolites produced. As previously reported for the rat, metabolites derived from sequential ω-following by β…

0301 basic medicineMalemedicine.medical_specialtyHealth Toxicology and MutagenesisMetabolitePhthalic AcidsHamsterPeroxisome Proliferation010501 environmental sciencesToxicology01 natural sciencesMicrobodies03 medical and health scienceschemistry.chemical_compoundOral administrationInternal medicineCricetinaeDiethylhexyl PhthalatemedicineAnimals0105 earth and related environmental sciences030102 biochemistry & molecular biologyPublic Health Environmental and Occupational HealthPhthalateMetabolismPeroxisomeRatsEndocrinologychemistryLiverGlucuronideOxidation-ReductionToxicology and industrial health
researchProduct

Glucagon-like peptide-2 reduces the obesity-associated inflammation in the brain.

2018

Growing evidence suggests a link between obesity and neurodegeneration. The purpose of the present study was to explore the neuroprotective potential of glucagon-like peptide-2 (GLP-2) in the brain of high fat diet (HFD)-fed mice. Markers of inflammation and oxidative stress were analysed in the brains of obese mice chronically treated with [Gly2]-GLP-2 (teduglutide), the stable analogue of the GLP-2, and they were compared to age-matched untreated obese and lean animals. Neurodegeneration was examined by TUNEL assay. HFD feeding increased the expression of pro-inflammatory mediators (NF-kB, IL-8, TNF-α, IL-1β and IL-6), glial fibrillary acidic protein (GFAP), index of gliosis and neurodege…

0301 basic medicineMalemedicine.medical_specialtyInflammationmedicine.disease_causeDiet High-FatSettore BIO/09 - FisiologiaNeuroprotectionlcsh:RC321-57103 medical and health sciences0302 clinical medicineNeuroinflammationInternal medicinemedicineGlucagon-Like Peptide 2AnimalsObesityNeurodegenerationlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryNeuroinflammationTUNEL assayGlial fibrillary acidic proteinbiologyChemistryNeurodegenerationdigestive oral and skin physiologyBrainmedicine.diseaseMice Inbred C57BL030104 developmental biologyEndocrinologyNeuroprotective AgentsNeurologyGliosisOxidative stressAstrocytesbiology.proteinGlucagon-Like Peptide-2 ReceptorOxidative streEncephalitismedicine.symptomInflammation MediatorsGLP-2030217 neurology & neurosurgeryOxidative stresshormones hormone substitutes and hormone antagonistsNeurobiology of disease
researchProduct

Lorcaserin bidirectionally regulates dopaminergic function site-dependently and disrupts dopamine brain area correlations in rats

2020

Abstract Lorcaserin, which is a selective agonist of serotonin2C receptors (5-HT2CRs), is a new FDA-approved anti-obesity drug that has also shown therapeutic promise in other brain disorders, such as addiction and epilepsy. The modulation of dopaminergic function might be critical in the therapeutic effect of lorcaserin, but its exact effect is unknown. Here, we studied the effect of the peripheral administration of lorcaserin on the ventral tegmental area (VTA), the substantia nigra pars compacta (SNc) dopaminergic neural activity, dopamine (DA) dialysis levels in the nucleus accumbens and striatum and on DA tissue levels in 29 different rat brain regions. Lorcaserin (5–640 μg/kg, i.v.) m…

0301 basic medicineMalemedicine.medical_specialtySerotoninDopamineSubstantia nigraStriatumNucleus accumbensSettore BIO/09 - FisiologiaLorcaserinIntracerebral microdialysisRats Sprague-DawleyDose-Response Relationship03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineSingle cell extracellular recordingsRewardDopamineInternal medicineReceptor Serotonin 5-HT2CmedicineAnimals5-HT2CObesityPharmacologyDose-Response Relationship DrugPars compactaChemistryDopaminergic NeuronsDopaminergicBrainNeurochemistryBenzazepinesSerotonin2C receptorRatsVentral tegmental area030104 developmental biologyEndocrinologymedicine.anatomical_structurenervous systemSprague-DawleyDrugIntracerebral microdialysis; Neurochemistry; Obesity; Reward; Serotonin2C receptor; Single cell extracellular recordings; Animals; Benzazepines; Brain; Dopamine; Dopaminergic Neurons; Dose-Response Relationship Drug; Male; Rats; Rats Sprague-Dawley; Receptor Serotonin 5-HT2C; Serotonin 5-HT2 Receptor AgonistsIntracerebral microdialysi030217 neurology & neurosurgerySerotonin 5-HT2 Receptor Agonistsmedicine.drugReceptor
researchProduct

Dietary protein restriction reduces circulating VLDL triglyceride levels via CREBH-APOA5-dependent and -independent mechanisms

2018

Hypertriglyceridemia is an independent risk factor for cardiovascular disease. Dietary interventions based on protein restriction (PR) reduce circulating triglycerides (TGs), but underlying mechanisms and clinical relevance remain unclear. Here, we show that 1 week of a protein-free diet without enforced calorie restriction significantly lowered circulating TGs in both lean and diet-induced obese mice. Mechanistically, the TG-lowering effect of PR was due, in part, to changes in very low-density lipoprotein (VLDL) metabolism both in liver and peripheral tissues. In the periphery, PR stimulated VLDL-TG consumption by increasing VLDL-bound APOA5 expression and promoting VLDL-TG hydrolysis and…

0301 basic medicineMalemedicine.medical_specialtyVery low-density lipoproteinDietary proteinFGF21Calorie restrictionmTORC1Lipoproteins VLDLMechanistic Target of Rapamycin Complex 1Protein Serine-Threonine Kinases03 medical and health sciencesMice0302 clinical medicineRisk FactorsInternal medicinemedicineDiet Protein-RestrictedIntegrated stress responseAnimalsHumansCyclic AMP Response Element-Binding ProteinTriglyceridesRandomized Controlled Trials as TopicHypertriglyceridemiaChemistryHydrolysisHypertriglyceridemianutritional and metabolic diseasesGeneral Medicinemedicine.diseaseLipid Metabolism030104 developmental biologyEndocrinologyApolipoproteinsHypotriglyceridemiaLiverApolipoprotein A-Vlipids (amino acids peptides and proteins)Female030217 neurology & neurosurgeryLipoproteinResearch Article
researchProduct

Sex hormones modulate pathogenic processes in experimental traumatic brain injury.

2018

Clinical and animal studies have revealed sex-specific differences in histopathological and neurological outcome after traumatic brain injury (TBI). The impact of perioperative administration of sex steroid inhibitors on TBI is still elusive. Here, we subjected male and female C57Bl/6N mice to the controlled cortical impact (CCI) model of TBI and applied pharmacological inhibitors of steroid hormone synthesis, that is, letrozole (LET, inhibiting estradiol synthesis by aromatase) and finasteride (FIN, inhibiting dihydrotestosterone synthesis by 5α-reductase), respectively, starting 72 h prior CCI, and continuing for a further 48 h after CCI. Initial gene expression analyses showed that andro…

0301 basic medicineMalemedicine.medical_specialtyanimal structuresmedicine.drug_classmedicine.medical_treatmentTropomyosin receptor kinase BTropomyosin receptor kinase ABiochemistryNeuroprotection03 medical and health sciencesCellular and Molecular NeuroscienceMice0302 clinical medicineInternal medicineBrain Injuries TraumaticmedicineAnimalsNerve Growth FactorsSex CharacteristicsbiologyEstradiolbusiness.industryEstrogen AntagonistsBrainDihydrotestosteroneAndrogennervous system diseasesMice Inbred C57BLSteroid hormoneDisease Models Animal030104 developmental biologyEndocrinologynervous systemSex steroidDihydrotestosteronebiology.proteinFemalebusiness030217 neurology & neurosurgeryNeurotrophinmedicine.drugJournal of neurochemistry
researchProduct

Delirium Predisposing and Triggering Factors in Nursing Home Residents: A Cohort Trial-Nested Case-Control Study.

2019

Background Delirium is a common geriatric syndrome, with a prevalence of between 15-70% among older long-term care residents. It is associated with adverse outcomes, and its onset may prove imperceptible to health professionals. Few studies in institutionalized older people have analyzed the predictors of delirium. Objective The aim of the present study was to identify delirium predisposing and triggering factors, and develop a predictive model. Methods A cohort trial-nested case-control study covering a period of 12 consecutive months (April 2015 - March 2016) was carried out. Predisposing and triggering episodes of delirium were recorded. Results A total of 443 older persons were recruite…

0301 basic medicineMalemedicine.medical_specialtymedicine.drug_classPsychological interventionCholinergic AntagonistsCohort Studies03 medical and health sciences0302 clinical medicinemental disordersAnticholinergicmedicineDementiaHomes for the AgedHumansAgedAged 80 and overbusiness.industryGeneral NeuroscienceIncidence (epidemiology)Area under the curveDeliriumGeneral Medicinemedicine.diseasePrecipitating FactorsNursing HomesPsychiatry and Mental healthClinical Psychology030104 developmental biologyCase-Control StudiesCohortNested case-control studyEmergency medicineDeliriumAccidental FallsDementiaFemaleGeriatrics and Gerontologymedicine.symptombusiness030217 neurology & neurosurgeryJournal of Alzheimer's disease : JAD
researchProduct

Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin.

1993

Since 1972, a large number of studies have shown that intravesical treatment with doxorubicin (adriamycin) is effective against carcinoma in situ and multiple papillary tumors. Furthermore, it significantly reduces the recurrence rate after transurethral resection. Its efficacy has been compared with that of Bacillus Calmette-Guerin (BCG), which is the only treatment accepted by the US Food and Drug Administration for therapy of carcinoma in situ (Tis). In more recent years, a few studies have been performed using intravesical epirubicin in the hope that different properties of the molecule might enhance the activity of the anthracyclines, but produce fewer and milder side-effects. After we…

0301 basic medicineMalemedicine.medical_specialtymedicine.medical_treatment030106 microbiologyUrologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawMedicineHumansPharmacology (medical)DoxorubicinEpirubicinPharmacologyChemotherapyUrinary bladderbusiness.industryCarcinoma in situCancermedicine.diseaseSurgeryInfectious Diseasesmedicine.anatomical_structureAdministration IntravesicalOncologyUrinary Bladder NeoplasmsDoxorubicin030220 oncology & carcinogenesisChemoprophylaxisbusinessCarcinoma in SituEpirubicinmedicine.drugJournal of chemotherapy (Florence, Italy)
researchProduct

Decrease in αβ/γδ T-cell ratio is accompanied by a reduction in high-fat diet-induced weight gain, insulin resistance, and inflammation.

2018

The implication of αβ and γδ T cells in obesity-associated inflammation and insulin resistance (IR) remains uncertain. Mice lacking γδ T cells show either no difference or a decrease in high-fat diet (HFD)-induced IR, whereas partial depletion in γδ T cells does not protect from HFD-induced IR. αβ T-cell deficiency leads to a decrease in white adipose tissue (WAT) inflammation and IR without weight change, but partial depletion of these cells has not been studied. We previously described a mouse model overexpressing peroxisome proliferator-activated receptor β (PPAR-β) specifically in T cells [transgenic (Tg) T-PPAR-β] that exhibits a partial depletion in αβ T cells and no change in γδ T-ce…

0301 basic medicineMalemedicine.medical_specialtymedicine.medical_treatmentT cellReceptors Antigen T-Cell alpha-betaT-LymphocytesAdipose tissueInflammationWhite adipose tissueDiet High-FatWeight GainBiochemistry03 medical and health sciencesMice0302 clinical medicineImmune systemInsulin resistanceInternal medicineGlucose IntoleranceGeneticsmedicineAnimalsObesityMolecular BiologyInflammationChemistryInsulinWeight changeBody Weightfood and beveragesnutritional and metabolic diseasesReceptors Antigen T-Cell gamma-deltamedicine.diseaseMice Inbred C57BL030104 developmental biologyEndocrinologymedicine.anatomical_structurelipids (amino acids peptides and proteins)medicine.symptomInsulin Resistancehormones hormone substitutes and hormone antagonists030217 neurology & neurosurgeryBiotechnologyFASEB journal : official publication of the Federation of American Societies for Experimental Biology
researchProduct

Influence of endogenous glucagon-like peptide-2 on lipid disorders in mice fed a high-fat diet

2016

Aim: The purpose of the present study was to investigate the influence of endogenous glucagon-like peptide-2 (GLP-2) on lipid profile in mice fed a standard diet (STD) or a high-fat diet (HFD). Materials and methods: HFD- and age-matched STD mice were injected once a day with GLP-2 (3-33), a GLP-2 receptor (GLP-2R) antagonist, or vehicle for 4 weeks. Results: HFD mice displayed increased intrahepatic lipid concentration and hepatic steatosis and higher plasma concentrations of cholesterol, LDL, AST, and ALT than STD mice. No difference was observed in lipid fecal elimination. In STD mice, the chronic treatment with GLP-2 (3-33) did not affect any parameter, while in HFD mice, it enhanced pl…

0301 basic medicineMalemedicine.medical_specialtyobesityEndogenyBiologyDiet High-FatliverSettore BIO/09 - Fisiologia03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineInsulin resistanceEndocrinologyMetabolic DiseaseslipidInternal medicineinsulin resistancemedicineGlucagon-Like Peptide 2AnimalsReceptormedicine.diagnostic_testCholesterolSettore BIO/16 - Anatomia Umanadigestive oral and skin physiologyAntagonistGeneral Medicinemedicine.diseaseGlucagon-like peptide-2LipidsPeptide FragmentsMice Inbred C57BL030104 developmental biologyEndocrinologychemistrylipids (amino acids peptides and proteins)030211 gastroenterology & hepatologySteatosisLipid profileGLP-2hormones hormone substitutes and hormone antagonists
researchProduct